Recent Investment Analysts’ Ratings Changes for Axsome Therapeutics (AXSM)

Several analysts have recently updated their ratings and price targets for Axsome Therapeutics (NASDAQ: AXSM):

• 10/26/2026 – Axsome Therapeutics had its price target lowered by Piper Sandler from $258.00 to $238.00. They now have an “overweight” rating on the stock.
• 10/15/2026 – Axsome Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/14/2026 – Axsome Therapeutics had its “outperform” rating reaffirmed by Royal Bank Of Canada.
• 10/8/2026 – Axsome Therapeutics had its price target lowered by Royal Bank Of Canada from $297.00 to $295.00. They now have an “outperform” rating on the stock.
• 9/29/2026 – Axsome Therapeutics had its price target lowered by Deutsche Bank Aktiengesellschaft from $280.00 to $267.00. They now have a “buy” rating on the stock.
• 9/25/2026 – Axsome Therapeutics had its price target lowered by Morgan Stanley from $251.00 to $247.00. They now have an “equal weight” rating on the stock.
• 9/25/2026 – Axsome Therapeutics had its “buy” rating reaffirmed by HC Wainwright.
• 9/23/2026 – Axsome Therapeutics had its price target raised by Truist Financial from $200.00 to $285.00. They now have a “buy” rating on the stock.
• 9/18/2026 – Axsome Therapeutics had its “overweight” rating reaffirmed by Piper Sandler. They now have a $258.00 price target on the stock.
• 8/31/2026 – Axsome Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $290.00 price target on the stock.

Insider Buying and Selling at Axsome Therapeutics

In other news, COO Mark L. Jacobson sold 10,000 shares of the stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $208.65, for a total transaction of $2,086,500.00. Following the completion of the transaction, the chief operating officer owned 10,000 shares in the company, valued at approximately $2,086,500. This represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Herriot Tabuteau sold 4,660 shares of Axsome Therapeutics stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $213.95, for a total value of $997,007.00. Following the completion of the sale, the chief executive officer directly owned 7,229 shares of the company’s stock, valued at approximately $1,546,644.55. This trade represents a 39.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 59,664 shares of company stock worth $12,624,805. Corporate insiders own 20.60% of the company’s stock.

Axsome Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system (CNS) disorders. Founded in 2012 and headquartered in New York, the company develops medicines for conditions with significant unmet medical needs, including depression, narcolepsy, excessive daytime sleepiness, and other neurological disorders.

Axsome’s commercial products include Auvelity (dextromethorphan and bupropion), an oral treatment approved in the United States for major depressive disorder in adults, and Sunosi (solriamfetol), a therapy for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.